Lexaria Bioscience Corp. announced on February 20, 2025, a strategic business decision to further investigate the commercial opportunities for orally taken liraglutide processed with its DehydraTECH technology. Liraglutide, a major GLP-1 drug, went off-patent last year, presenting a unique market opportunity.
The company has already filed patent applications related to DehydraTECH-enhanced oral liraglutide, aiming to develop and potentially sell the world's first oral capsule or tablet version of the drug. This strategic move is supported by successful animal study results from November 20, 2024, where DehydraTECH-liraglutide outperformed the Rybelsus® control group in blood sugar and body weight control by 11.53% and 11.13% respectively.
Lexaria is also preparing to commence pilot clinical testing of DehydraTECH-liraglutide in humans, following independent ethics board approval received on January 15, 2025. If successful, this could lead to an accelerated regulatory approval pathway with the FDA, addressing an unmet market need for an oral liraglutide alternative to current injectable forms.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.